Printer Friendly

BREAST CANCER CLINICAL TRIALS OPEN IN NASHVILLE AREA; INFORMATION AVAILABLE VIA TOLL-FREE NUMBER

 COLLEGEVILLE, Pa., July 6 /PRNewswire/ -- Rhone-Poulenc Rorer (NYSE: RPR) announced today the opening of a new breast cancer clinical trial in the Nashville area for the investigational anticancer drug, Taxotere(R).
 Access to information on the RPR sponsored clinical trial is available to physicians and patients by calling 1-800-RX-TRIAL, a toll- free hotline. Callers will be greeted by clinical specialists who pre- screen and direct calls to the appropriate contact at the trial site. In addition, the 1-800-RX-TRIAL number can also inform callers about clinical trials conducted at sites through-out the country for other types of cancer.
 "Clinical trials are the only means of demonstrating the safety and efficacy of a new compound," said Terry Plasse, M.D., Director of Oncology at Rhone-Poulenc Rorer. "We hope the toll-free number will help identify patients and physicians who can benefit from learning about entry criteria and trial site location. Together, we can aid in the fight against cancer by increasing the speed with which a new drug comes to market. "While the Nashville area clinical trial is for breast cancer only, Taxotere(R) is currently being tested in the following cancer types around the country: breast, ovarian, adult acute leukemia, pediatric tumors, melanoma, non-Hodgkin's lymphoma, soft tissue sarcoma, and cancers of the stomach, prostate, pancreas, bladder, cervix and head and neck.
 Taxotere(R) belongs to a unique class of anti-cancer agents called taxoids. Taxoids have been found to inhibit cancer cell division by acting on the cell's internal skeleton, which is made up of elements called microtubules. Microtubules assemble and disassemble during the cell cycle, but Taxotere(R) blocks the disassembly, thus preventing cancer cells from dividing.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. The company reported sales of $4.1 billion and invested over $500 million in research and development in 1992.
 /delval/
 -0- 7/6/93
 /CONTACT: Rob Partridge, 215-454-3890, or Bob Pearson, 215-454-3872/
 (RPR)


CO: Rhone-Poulenc Rorer ST: Tennessee, Pennsylvania IN: MTC SU:

MK -- PH007 -- 8543 07/06/93 10:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1993
Words:344
Previous Article:PENNSYLVANIA TURNPIKE ISSUES TRAFFIC ADVISORY
Next Article:HEALTH IMAGES, INC. COMMENTS ON PRESS REPORTS
Topics:


Related Articles
TAXOL APPROVAL CAPS YEARS OF EFFORT
TOLL-FREE NUMBER AVAILABLE FOR TAXOTERE(R) CLINICAL TRIALS
BREAST CANCER CLINICAL TRIALS OPEN IN PHILADELPHIA AREA; INFORMATION AVAILABLE VIA TOLL-FREE NUMBER
BREAST CANCER CLINICAL TRIALS OPEN IN PRINCETON, NEW JERSEY AREA; INFORMATION AVAILABLE VIA TOLL-FREE NUMBER
BREAST CANCER CLINICAL TRIALS OPEN IN READING AREA; INFORMATION AVAILABLE VIA TOLL-FREE NUMBER
NSABP TO BEGIN NEW TRIAL OF TAXOTERE(R) (DOCETAXEL) FOR WOMEN WITH OPERABLE BREAST CANCER
TAXOTERE (docetaxel) CLEARED FOR USE AS A TREATMENT FOR PATIENTS WITH ADVANCED BREAST CANCER IN UNITED STATES
Isis Begins Phase II Trials of Antisense Anticancer Drug; Isis Receives Milestone Payment from Novartis
Isis Presents Phase I Results of Antisense Anticancer Compound; Phase I Clinical Program Completed
Barr Launches 'tamoxifencitrate.com' Web Site, Risk Assessment Toll Free Number.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters